Impact of Pharmacotherapy on Interstage Mortality and Weight Gain in Children with Single Ventricle
- 16 November 2012
- journal article
- research article
- Published by Computers, Materials and Continua (Tech Science Press) in Congenital Heart Disease
- Vol. 8 (3), 219-227
- https://doi.org/10.1111/chd.12020
Abstract
OBJECTIVE.: Infants with single ventricle physiology have a high mortality and poor somatic growth during the interstage period. We retrospectively assessed the impact of pharmacotherapy in this population using a multicenter database. DESIGN AND RESULTS.: Records for 395 patients (63.5% boys) with single ventricle were obtained from the National Pediatric Cardiology Quality Improvement Collaborative registry. Median of five medications were prescribed per patient at discharge after stage 1 palliation (interquartile range 3 to 6); the most common medications being aspirin (95.7%), diuretics (90.4%), angiotensin convertase enzyme inhibitors (37.7%), proton pump inhibitors (33.4%), H2 receptor blockers (30.6%), and digoxin (27.6%). Interstage mortality was 9.4%. Digoxin use was associated with lower risk of death (P =.03) on univariable analysis, however no single medication was an independent predictor on regression analysis. Change in weight-for-age z-score was studied as outcome of somatic growth with 36.3% patients showing a decrease during the interstage period. Total number of medications prescribed to a patient showed a negative correlation with the interstage change in z-score (r = -0.19, P =.002). On univariable comparisons, use of metoclopramide and lansoprazole were associated with decreased z-score (P =.004 and.041, respectively) although linear regression failed to identify any agent as independent predictor. CONCLUSIONS.: Children with single ventricle have high mortality and a profound medication burden. No individual medication is independently associated with better survival or weight gain during interstage period. Despite widespread use, proton pump inhibitors and prokinetic agents are not associated with better outcomes and may be associated with poor growth.Keywords
This publication has 38 references indexed in Scilit:
- Evolution of treatment options and outcomes for hypoplastic left heart syndrome over an 18-year periodThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Risk factors for interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variantsThe Journal of Thoracic and Cardiovascular Surgery, 2008
- Feeding Difficulties and Growth Delay in Children with Hypoplastic Left Heart Syndrome versus d-Transposition of the Great ArteriesPediatric Cardiology, 2007
- Growth and correlates of nutritional status among infants with hypoplastic left heart syndrome (HLHS) after stage 1 Norwood procedureNutrition, 2006
- Right Ventricle to Pulmonary Artery Conduit Reduces Interim Mortality After Stage 1 Norwood for Hypoplastic Left Heart SyndromeThe Annals of Thoracic Surgery, 2004
- Risk Factors for Interstage Death After the Norwood ProcedurePediatric Cardiology, 2004
- Prevention of Early Sudden Circulatory Collapse After the Norwood OperationCirculation, 2004
- Impact of right ventricle to pulmonary artery conduit on outcome of the modified norwood procedureThe Annals of Thoracic Surgery, 2004
- Home surveillance program prevents interstage mortality after the Norwood procedureThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Interim mortality in infants with systemic-to–pulmonary artery shuntsThe Annals of Thoracic Surgery, 2003